Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00086346 · ClinicalTrials.gov registry record · Phase 3
Study Evaluating of Calcineurin Inhibitor and Sirolimus (Rapamune) Treatment in Liver Transplant Recipients
A Phase 3 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 607
- Enrollment target
NCT00086346 is a Phase 3 study that was terminated before completion, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 607 participants.
The verdict
NCT00086346, a Phase 3 study, was terminated before completion, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 607 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the sirolimus conversion regimen as compared with the calcineurin inhibitor continuation regimen with regards to renal function in stable liver transplant subjects.
Interventions
- DRUG Sirolimus (Rapamune)
- DRUG Cyclosporine or Tacrolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 607 participants |
| Start Date | 2002-12 |
| Est. Completion | 2008-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00086346
The ClinicalTrials.gov registry entry for NCT00086346 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 607 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sirolimus (Rapamune) is the first listed.
NCT00086346 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00086346 about?
NCT00086346 is a clinical study titled "Study Evaluating of Calcineurin Inhibitor and Sirolimus (Rapamune) Treatment in Liver Transplant Recipients". The purpose of this study is to evaluate the sirolimus conversion regimen as compared with the calcineurin inhibitor continuation regimen with regards to renal function in stable liver transplant subjects.
What is the current status of trial NCT00086346?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 607 participants. The study started on 2002-12. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00086346?
The interventions under investigation include: Sirolimus (Rapamune) (DRUG), Cyclosporine or Tacrolimus (DRUG).
Who is sponsoring clinical trial NCT00086346?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.